Immunosuppression, liver injury and post‐transplant HCV recurrence
Authors:
- 7 November 2011
- journal article
- review article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 19 (1) , 1-8
Abstract
Summary. Hepatitis C virus (HCV) infection is a major cause for liver transplantation worldwide. Still, HCV re‐infection of the graft occurs in almost all cases. Most liver transplant recipients experience episodes of graft hepatitis associated with fibrosis progression and graft failure. Clinical management of graft hepatitis can be challenging as in addition to rejection and HCV‐induced hepatitis various other factors might be involved including toxic liver injury, steatohepatitis, ischaemic bile duct lesions or infections with other pathogens. Treatment options are often contradictory for different causes of graft hepatitis, and the role of distinct immunosuppressive drugs has been discussed controversially. Corticosteroids increase the infectivity of HCV by altering expression levels of entry factors and other immunosuppressive agents may have diverse effects on HCV replication and fibrosis progression. Interferon alpha‐therapy of hepatitis C shows limited efficacy and tolerability in liver transplant recipients and may also cause rejection. In this review we summarize the current knowledge on mechanisms of liver injury in post‐transplant hepatitis C, discuss the pros and cons of immunosuppressive agents in this specific setting and describe potential novel approaches to prevent HCV reinfection.Keywords
This publication has 79 references indexed in Scilit:
- Progress in the development of preventive and therapeutic vaccines for hepatitis C virusJournal of Hepatology, 2011
- Hepatitis C virus–infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than menHepatology, 2011
- Differential In Vitro Effects of Intravenous versus Oral Formulations of Silibinin on the HCV Life Cycle and InflammationPLOS ONE, 2011
- The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entryHepatology, 2010
- Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantationJournal of Experimental Medicine, 2010
- Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A #Hepatology, 2009
- The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients #Hepatology, 2009
- Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs # †Hepatology, 2009
- Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivoHepatology, 2008
- Treating viral hepatitis C: efficacy, side effects, and complicationsGut, 2006